Overview
Work History
Education
Postgraduate training
Publications
Languages
Timeline
Generic

Pamela Celiz

Sitges

Overview

17
17
years of professional experience

Work History

Medical Oncologist

Instituto Català D'Oncologia
01.2022 - Current

Medical Oncologist

Hospital Del Mar
01.2021 - 02.2022

Scientific Manager/ Medical Manager

SOLTI-Breast Cancer Research Group
01.2017 - 11.2020

Medical Oncologist

Hospital Universitario 12 de Octubre, Madrid
01.2013 - 11.2016

Medical Oncologist

Hospital Germans Trias I Pujol
01.2008 - 03.2012

Education

Fellowship - Urological Tumors

Hospital Universitario 12 De Octubre
Madrid
2015

Ph.D. - Medicine

Universidad Autonoma De Barcelona
Barcelona
10.2012

Medical Oncologist -

Universidad Católica De Cordoba
Argentina
01.2008

Medical Doctor -

Universidad Católica De Córdoba
Argentina
01.2003

Postgraduate training

  • PhD in Medicine, 2012- Prognostic and predictive factors of response in patients with locally advanced bladder carcinoma treated with neoadjuvant chemotherapy.
  • Fellowship in Urological Tumors, 2013-2015, Hospital Universitario 12 de Octubre

Publications

  • Font A, Taron M, Gago JL, Costa C, Sánchez JJ, Carrato C, Mora M, Celiz P, Perez L, Rodríguez D, Gimenez-Capitan A, Quiroga V, Benlloch S, Ibarz L, Rosell R. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol. 2011 Jan;22(1):139-144. IF: 7.3
  • Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial The Lancet Oncology 2020. 21-1, pp.33-43. IF: 41,3
  • Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. Front Oncol 2021;11;645026. IF: 5,3
  • Fort-Casamartina, E., Muñoz-Sanchez, C., Rigo-Bonnin, R.F. et al. First reported double drug–drug interaction in a cancer renal patient under everolimus treatment: therapeutic drug monitoring and review of literature. Eur J Med Res 28, 202 (2023). IF: 4,2

Languages

English
Advanced (C1)

Timeline

Medical Oncologist

Instituto Català D'Oncologia
01.2022 - Current

Medical Oncologist

Hospital Del Mar
01.2021 - 02.2022

Scientific Manager/ Medical Manager

SOLTI-Breast Cancer Research Group
01.2017 - 11.2020

Medical Oncologist

Hospital Universitario 12 de Octubre, Madrid
01.2013 - 11.2016

Medical Oncologist

Hospital Germans Trias I Pujol
01.2008 - 03.2012

Fellowship - Urological Tumors

Hospital Universitario 12 De Octubre

Ph.D. - Medicine

Universidad Autonoma De Barcelona

Medical Oncologist -

Universidad Católica De Cordoba

Medical Doctor -

Universidad Católica De Córdoba
Pamela Celiz